DocWire News Editors

DocwireNews

<p>The FDA has recently given 510(k) clearance MolecuLight i:X, a handheld device that uses fluorescent light imaging to detect <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/increased-risk-of-chronic-myeloid-leukemia-following-gastric-conditions-indicating-helicobacter-pylori-infection-a-case-control-study/">infected wounds</a>. This clearance expands upon the de novo clearance that the technology was granted on August 14, 2018. MolecuLight i:X allows users to utilize real-time point-of-care visualization of fluorescence in wounds while measuring and digitally recording all images and readings.</p>
<p>When used in combination with clinical signs and symptoms (CSS), i:X&#8217;s fluorescence image has been shown to increase the physician’s ability to identify wounds with bacterial concentrations above 104 CFU/g (colony-forming units per gram), in comparison to the examination of symptoms alone. Moleculight i:x has received CE marking for European sales and is approved by Health Canada as well.</p>
<p>“The granting of our 510(k) clearance by the FDA for the i:X handheld fluorescence imaging device is very exciting and is a further validation of the growing clinical evidence supporting the utility of our imaging platform,” noted Anil Amlani, MolecuLight’s CEO, in a press release. “Bacteria at loads of 104 CFU/g have been shown to delay wound healing, resulting in poor patient quality of life and high wound care costs worldwide. Identifying wounds with bacterial loads of &gt;104 CFU/g at the point-of-care enables the clinician using the MolecuLight i:X to provide more appropriate, targeted treatment.</p>
<p>MolecuLight received this clearance after submitting the results from a 350 patient, 14 sites and 20 physician clinical trials to the <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-new-firstline-nsclc-drug-combo/">FDA</a>. This study showed that the use of MolecuLight i:X and CSS together resulted in a three-fold increase in both sensitivity and diagnostic odds ratio in the number of wounds identified as having a bacterial load over 104 CFU/g compared to just using CSS alone. This jump in sensitivity was seen consistently in various clinical study sites and amongst an array of doctors analyzing wounds of diverse types and sizes.  Microbiology confirmed the three-fold increase in diagnostic odds ratio, which measured the overall effectiveness of the diagnostic tests.</p>
<p><iframe loading="lazy" src="https://www.youtube.com/embed/CbiKg5kuUek" width="770" height="434" frameborder="0" allowfullscreen="allowfullscreen"></iframe><br />
In other recent news surrounding MolecuLight, the company was recently told by the American Medical Association (AMA) that in its summary of panel actions from its September 2019 meeting, the CPT® Editorial Panel accepted to add the new Category III codes 0X30T and 0X31T to report &#8220;wound bacterial localization and treatment. &#8221; This is designed to enable a pathway for reimbursement for point-of-care fluorescence wound imaging and will be effective on July 1, 2020, at which point the novel code excluding the &#8220;X&#8221; will be reported by the AMA once the final data are distributed.</p>
<p>&#8220;Our clinical study results demonstrate that the i:X used in combination with CSS significantly increases the ability of clinicians to identify wounds with the presence of these bacterial loads when compared with wound assessment based on CSS,” said Amlani.</p>
<blockquote class="twitter-tweet" data-lang="en">
<p dir="ltr" lang="en">MolecuLight FDA Cleared to Detect Bacteria Infected Wounds <a href="https://t.co/25XugPdsLI">https://t.co/25XugPdsLI</a> <a href="https://t.co/7f5f76xS2z">pic.twitter.com/7f5f76xS2z</a></p>
<p>— primrose@acn (@primrose_acn) <a href="https://twitter.com/primrose_acn/status/1204444808988655616?ref_src=twsrc%5Etfw">December 10, 2019</a></p></blockquote>
<p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p>


Cecilia Brown

IASLC and LCRF Award Team Science Grant for Work on Immune-Based Approaches to Target Drug-Resistant Lung Cancer Cells

Lung Cancer

Emily Menendez

Zanidatamab Gains Accelerated Approval by FDA for Metastatic HER2+ BTC

Bile Duct Cancer

Laura Litwin

Phase 2 Study Evaluates Maintenance Atezolizumab Plus Talazoparib in ES-SCLC

Small Cell Lung Cancer

Latest News

FDA Clears MolecuLight i:X, a Fluorescence Imaging Device for Wound Management

Medical Devices

The FDA has recently given 510(k) clearance MolecuLight i:X, a handheld device that uses fluorescent light imaging to detect infected wounds. This clearance expands upon the ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe